«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2018 06

Page:

920-923

Research Field:

Publishing date:

Info

Title:

The change of advanced ovarian cancer CA125 before and after neoadjuvant chemotherapy and its correlation with tumor cytoreduction satisfaction degree and prognosis

Author(s):

Ma Qianqian; Ma Ling

Department of Gynecology,The First Affiliated Hospital of Bengbu Medical College,Anhui Bengbu 233004,China.

Keywords:

advanced ovarian cancer; neoadjuvant chemotherapy; change of CA125; tumor cytoreduction satisfaction degree; prognosis

PACS:

R737.31

DOI:

10.3969/j.issn.1672-4992.2018.06.026

Abstract:

Objective:To study the change of blood CA125 value in advanced ovarian cancer patients before and after neoadjuvant chemotherapy and its relationship with the prognosis and tumor cytoreduction satisfaction degree.Methods:From the 1st affiliated hospital of bengbu medical college tumor by pelvic masses of department of gynaecology puncture pathology diagnosed with ovarian cancer and after 1~2 cycle after neoadjuvant chemotherapy performed tumor cytoreduction surgery,clinical data of 70 patients with advanced ovarian cancer were retrospectiveal analysed.To analyse blood CA125 values of diagnosis and treatment for the first time,blood CA125 decline rate after neoadjuvant chemotherapy,and relationship between preoperative blood CA125 value and satisfaction and reduction of tumor and prognosis.Results:The t test and chi-square test suggested that one or two cycles after neoadjuvant chemotherapy,blood CA125 decline rate and preoperative CA125 levels affected the satisfaction of patients reduced tumor.Tumor cytoreduction satisfaction was campared between preoperative CA125 acuities ≤150 U/ml and >150 U/ml group,which difference was statistically significant(P＜0.05).The survival rate,had no statistically significant difference(P＞ 0.05).In Blood CA125 decline rate ≥80% and ＜80% group,tumor cytoreduction satisfacting degree had no statistically significant difference(P＞0.05).Conclusion:In 1~2 cycle after neoadjuvant chemotherapy,the decline rate of the blood CA125 and preoperative blood CA125 levels can predict the net rate for patients with surgery.Preoperative serum CA125 ≤150 U/ml or not and blood CA125 decline rate ≥80% or not could preliminarily estimate tumor cytoreduction satisfaction degree but can't predict the prognosis of patients.

References:

[1]Groeneweg JW,Foster R,Growdon WB,et al.Notch signaling in serous ovarian cancer［J］.J Ovarian Research,2014,7(1):95.
[2]Koshiyama M,Matsumura N,Konishi I.Recent concepts of ovarian carcinogenesis:Type I and type II［J］.BioMed Research International,2014,2014:1-11.
[3]Wen W,Wu J,Liu L,et al.Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer［J］.Molecular cancer,2015,14(1):100.
[4]Frigerio L,Ansaloni L,Poiasina E.Comprehensive management of epithelial ovarian cancer with peritoneal metastases［J］.World J Obstet Gynecol,2013,2:108-115.
[5]Ansaloni L,Coccolini F,Catena F.Cytoreductive surgery in primary advanced EOC［J］.World J Obstet Gynecol,2013,2:116-123.
[6]Lu HW,Xie LL,Lin ZQ.《2016NCCN Ovarian cancer clinical practice guidelines》 interpretation［J］.China J Practical Gynecology and Obstetrics,2016,32(8):761-768.［卢淮武,谢玲玲,林仲秋.《2016NCCN 卵巢癌临床实践指南 》 解读［J］.中国实用妇科与产科杂志,2016,32(8):761-768.］
[7]Bast RC.CA125 and the detection of recurrent ovarian cancer［J］.Cancer,2010,116(12):2850-2853.
[8]Torres-Lobatón A,Cifuentes G,Oliva-Posada JC,et al.Cáncer de ovario avanzado(Etapa clínica IIIc).Resultados del tratamiento quirúrgico en 100 pa-cientes［J］.GAMO,2013,12(1):24-31.
[9]Zang RY,Harter P,Chi DS,et al.Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort［J］.British J Cancer,2011,105(7):890-896.
[10]Chi DS,Venkatraman ES,Masson V,et al.The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma［J］.Gynecologic Oncology,2000,77(2):227-231.
[11]Liu HL,Cheng ZP.The role of CA125 in the screening,evaluation and prognosis of ovarian cancer［J］.Progress in Obstetrics and Gynecology,2016,25(8):636-639.［刘海伦,程忠平.CA125 不同计算方法在卵巢癌筛查,评估及预后方面的作用［J］.现代妇产科进展,2016,25(8):636-639.］
[12]Li J,Wu MF,Lin ZQ.《2012NCCNClinical practice guidelines for ovarian cancer including fallopian tube cancer and primary peritoneal cancer(Second Edition)》 interpretation［J］.International Journal of Obstetrics and Gynaecology,2012,39(2)：211-212.［李晶,吴妙芳,林仲秋.《2012NCCN卵巢癌包括输卵管癌和原发腹膜癌临床实践指南(第二版)》 解读［J］.国际妇产科学杂志，2012,39(2)：211-212.］
[13]Rodriguez N,Rauh-Hain JA,Shoni M,et al.Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy［J］.Gynecologic Oncology,2012,125(2):362-366.
[14]Wu J,Lin SN,Zhuo J.Dynamic monitoring of serum CA125 in patients with epithelial ovarian cancer［J］.Hebei Medical J,2012,18(10):1374-1376.［吴京,林珊娜,卓静.动态监测血清 CA125 对上皮性卵巢癌疗效及预后评估［J］.河北医学,2012,18(10):1374-1376.］
[15]Nan Yonggang，Wang Xiaomin，Lu Jianrong，et al.Study on the expression of CA125 in the cells and serum［J］.Modern Oncology,2016,24(17):2798-2800.［南永刚，王晓敏，陆建荣,等.CA125在肿瘤患者细胞和血清中表达相关性的研究［J］.现代肿瘤医学,2016,24(17):2798-2800.］
[16]Xi XW,Wan XP,Li SD,et al.The relationship between the level of serum CA125 in epithelial ovarian cancer after neoadjuvant chemotherapy decreased to half of the time required and operation rate and prognosis［J］.Chin J Obstetrics and Gynecology,2006,41(2):91-94.［席晓薇,万小平,李双弟,等.卵巢上皮性癌新辅助化疗后血清 CA125 水平下降至一半所需的时间与手术切净率及预后的关系［J］.中华妇产科杂志,2006,41(2):91-94.］

Memo

Memo:

-

Common functions

Last Update: 2018-01-29